TY - JOUR T1 - Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P2071 AU - Ana-Maria Vasile AU - Iustina Violeta Stan AU - Mihai Craiu AU - Valentina Daniela Comanici Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P2071.abstract N2 - Background and aim: Recently a new group of Gram-negative bacilli emerged among well documented germs involved in CF exacerbations. Stenotrophomonas maltophilia (SM), an aerobic Gram-negative opportunistic bacillus generates treatment issues due to high antimicrobial resistance. SM infection produces pulmonary function decline mostly in high-risk patients. The aim of our study was to describe the impact of SM infection in a pediatric regional center.Material and methods: Two years retrospective study was conducted for evaluating impact of SM pulmonary infection. We analyzed clinical data, cough-swab or sputum cultures, dynamic of pulmonary function tests and x-ray aspects. SM severe exacerbations were hospitalized and treated according to CF guides.Results: We evaluated a cohort of 50 patients during 322 visits, aged between 3 months and 33 years, with male predominance (62%). 5 of them (10%) were SM positive : 3 patients with acute exacerbation and 2 with chronic infection (>3 distinct episodes of positive cultures). Age range of patients was 8 months to 30 years. Sensitivity-guided treatment had favorable outcome in 4(80%) patients. An adult with a severe pulmonary impairment, chronic infection with Pseudomonas Aeruginosa [PA] and severe malnutrition, had a modest decline in FEV1 after cure. Lung-functional impairment of SM was significantly lower than in PA infection.Conclusion:1. SM exacerbations can be documented in ∼10% of CF patients in the era of anti-pseudomonal prophylaxis.2. Prognostic features of SM episodes are better than those of PA infection.3. SM infection has a poor prognostic when associated with other risk factors (low BMI, baseline low-FEV1, co-infections). ER -